Approximately 50% of General Electric's
Still, it is hard to deny that GE has been doing a lot of cosmetic surgery to some of its smaller body parts lately. Already this year, the company has plunked down $8.1 billion to acquire Abbott Laboratories'
To pay for this $14 billion splurge, it is widely expected that GE CEO Jeffery Immelt is shopping around the company's storied plastics business. According to a number of reports, he is hoping the division will fetch in the neighborhood of $10 billion.
I understand that Immelt wants to get out of the plastics business because it is not a fast-growing area, and that he prefers instead to focus on more rapidly expanding areas such as diagnostics, aerospace, and energy. To this end, I like the aerospace and energy acquisitions, but I don't like the moves into diagnostics or away from plastics.
Here's why. Just last week, GE announced that it had developed a new nano-ceramic material that was capable of withstanding extremely high temperatures. As a result, it is expected the company will be able to develop new and better-performing aircraft engines and gas turbines -- things that will aid in the growth of its aerospace and energy businesses.
This example of a new nanomaterial giving life to old ceramic products is just the type of boost that nanotechnology could also give to GE's lagging plastics business. After all, if nanotechnology can improve ceramic materials, why can't it also make any number of plastic products better, stronger, and lighter? My sense is that it can, and Immelt is missing an opportunity to apply this emerging technology to help to grow GE's plastic business.
Obviously, the decision is not mine to make, but if it is the commoditization of plastics that is driving Immelt out of that business, it is ironic that he wants to move aggressively into diagnostics.
This is because if there is one field where nanotechnology is likely to cause commoditization, it is in the diagnostics industry. For instance, new nanowires are being created by Nanosys -- an equity investment of Harris & Harris
Of course, there is more to the diagnostic business than just detecting disease, and many of these new devices will take some time to reach the commercial marketplace. But my point is that they are coming. Thus, I don't think the acquisition of Abbott's diagnostic business will have the long-term positive impact on GE's revenue and profits that Immelt is hoping for.
Just as real plastic surgery often begets more plastic surgery and, in so many cases, isn't really needed in the first place, so it is with GE's decision to "nip" its plastics business and "tuck" its diagnostic business. Bottom line: The conglomerate could be paying a lot for something that isn't really needed, and it would be better off just trying to take better care of its existing business.
- General Electric: A Finger in Every Pie
- GE Bulks Up: Fool by Numbers
- IBM Working Smarter, Not Harder: Fool by Numbers
- Innovate or Die
Fool contributor Jack Uldrich has never had plastic surgery, and he doesn't think you need it either, because you're beautiful just as you are. He owns stock in GE. The Fool's disclosure policy wants to tell you there's a great future in plastics. Think about it.
More from The Motley Fool
General Electric Stock Plummeted 44.8% in 2017: Here's What You Should Do
After General Electric's massive fall in 2017, is staying invested in the stock a risky bet or an opportunity?
What to Expect From General Electric Company in 2018
The industrial giant is trying to release value for investors after a difficult year.
3 Top Value Stocks to Buy in January
Are you looking for a bargain in today's pricy market? Start your search with these three stocks.